目的 探討石斛夜光丸聯(lián)合重組人表皮生長因子滴眼液治療干眼癥的臨床療效。方法 選擇2020年1月—2021年6月解放軍總醫(yī)院京南醫(yī)療區(qū)收治的120例干眼癥患者，按照隨機數(shù)字表法分為對照組和治療組，每組各60例。對照組外用重組人表皮生長因子滴眼液，直接滴入眼結膜囊內(nèi)，2～3滴/次，4次/d。在對照組的基礎上，治療組口服石斛夜光丸，7.3g/次，2次/d。兩組患者連續(xù)治療7d。觀察兩組患者臨床療效，比較治療前后兩組患者癥狀好轉時間，眼底淚膜破裂時間（BUT）、眼底中央淚河高度（TMH）和淚液分泌距離（SIT）水平，及血清因子白細胞介素-6（IL-6）、過氧化脂質(zhì)（LPO）、超氧化物歧化酶（SOD）和腫瘤壞死因子-α（TNF-α）水平。結果 治療后，治療組總有效率（98.33%）明顯高于對照組總有效率（83.33%，P＜0.05）。治療后，治療組患者癥狀好轉時間均明顯早于對照組（P＜0.05）。治療后，兩組患者BUT、SIT、TMH、SOD水平明顯升高，IL-6、LPO和TNF-α水平明顯降低（P＜0.05），且治療組BUT、SIT、TMH、IL-6、LPO、SOD和TNF-α水平明顯好于對照組（P＜0.05）。結論 重組人表皮生長因子滴眼液與石斛夜光丸聯(lián)合治療干眼癥療效確切，可有效改善干眼癥癥狀，增加淚液分泌，提高淚膜的保護性，有效降低炎性反應，且安全有效。

Objective To investigate the efficacy of ShihuYeguang Pills combined with Recombinant Human Epidermal Growth Factor Eye Drops in treatment of xerophthalmia. Methods Patients (120 cases) with xerophthalmia in Jingnan Medical District of PLA General Hospital from January 2020 to June 2021 were randomly divided into control and treatment group, and each group had 60 cases. Patients in the control group were administered with Recombinant Human Epidermal Growth Factor Eye Drops, dripped directly into the conjunctival sac, 2-3 drops/time, four times daily. Patients in the treatment group po administered with ShihuYeguang Pills on the basis of the control group, 7.3 g/time, twice daily. Patients in two groups were treated for 7 d. After treatment, the clinical evaluation was evaluated, the improvement time of symptom, the levels of BUT, SIT, TMH, IL-6, LPO, SOD, and TNF-α in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group (98.33%) was significantly higher than that of the control group (83.33%, P<0.05). After treatment, the time of symptom improvement in the treatment group was significantly earlier than that in the control group (P<0.05). After treatment, the levels of BUT, SIT, TMH, and SOD in two groups were significantly increased, while the levels of IL-6, LPO, and TNF-α were significantly decreased in two groups (P<0.05). The levels of BUT, SIT, TMH, IL-6, LPO, SOD, and TNF-α in the treatment group were significantly better than those in the control group (P<0.05). Conclusion The combination of Recombinant Human Epidermal Growth Factor Eye Drops and ShihuYeguang Pills is effective in the treatment of xerophthalmia, can effectively improve the symptoms, increase tear secretion, improve the protection of tear film, effectively reduce inflammatory reaction, and which is safe and effective.

R988.1

北京市科技計劃項目（Z211100002921049）